The production of more useful monoclonal antibodies I. Modifications of the basic technology

Deborah French, Ellyn Fischberg, Susan Buhl, Matthew D. Scharff

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hybridoma technology has greatly expanded the usefulness and application of immunoassays and created the potential for in-vivo immunodiagnosis and therapy. While the basic technique has not changed appreciably, a number of modifications have been introduced which make it possible to obtain more useful monoclonal antibodies and to generate monoclonals against weakly immunogenic substances. In this first part of a two-part review, Matthew Scharff and his colleagues review the most useful of these modifications in the production of animal monoclonal antibodies, paying particular attention to the problem of raising antibodies against small amounts of weak immunogens.

Original languageEnglish (US)
Pages (from-to)344-346
Number of pages3
JournalImmunology Today
Volume7
Issue number11
DOIs
StatePublished - 1986

Fingerprint

Monoclonal Antibodies
Technology
Immunologic Tests
Hybridomas
Immunoassay
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

The production of more useful monoclonal antibodies I. Modifications of the basic technology. / French, Deborah; Fischberg, Ellyn; Buhl, Susan; Scharff, Matthew D.

In: Immunology Today, Vol. 7, No. 11, 1986, p. 344-346.

Research output: Contribution to journalArticle

French, Deborah ; Fischberg, Ellyn ; Buhl, Susan ; Scharff, Matthew D. / The production of more useful monoclonal antibodies I. Modifications of the basic technology. In: Immunology Today. 1986 ; Vol. 7, No. 11. pp. 344-346.
@article{20b1262291654399b77e28b946f48a67,
title = "The production of more useful monoclonal antibodies I. Modifications of the basic technology",
abstract = "Hybridoma technology has greatly expanded the usefulness and application of immunoassays and created the potential for in-vivo immunodiagnosis and therapy. While the basic technique has not changed appreciably, a number of modifications have been introduced which make it possible to obtain more useful monoclonal antibodies and to generate monoclonals against weakly immunogenic substances. In this first part of a two-part review, Matthew Scharff and his colleagues review the most useful of these modifications in the production of animal monoclonal antibodies, paying particular attention to the problem of raising antibodies against small amounts of weak immunogens.",
author = "Deborah French and Ellyn Fischberg and Susan Buhl and Scharff, {Matthew D.}",
year = "1986",
doi = "10.1016/0167-5699(86)90142-8",
language = "English (US)",
volume = "7",
pages = "344--346",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - The production of more useful monoclonal antibodies I. Modifications of the basic technology

AU - French, Deborah

AU - Fischberg, Ellyn

AU - Buhl, Susan

AU - Scharff, Matthew D.

PY - 1986

Y1 - 1986

N2 - Hybridoma technology has greatly expanded the usefulness and application of immunoassays and created the potential for in-vivo immunodiagnosis and therapy. While the basic technique has not changed appreciably, a number of modifications have been introduced which make it possible to obtain more useful monoclonal antibodies and to generate monoclonals against weakly immunogenic substances. In this first part of a two-part review, Matthew Scharff and his colleagues review the most useful of these modifications in the production of animal monoclonal antibodies, paying particular attention to the problem of raising antibodies against small amounts of weak immunogens.

AB - Hybridoma technology has greatly expanded the usefulness and application of immunoassays and created the potential for in-vivo immunodiagnosis and therapy. While the basic technique has not changed appreciably, a number of modifications have been introduced which make it possible to obtain more useful monoclonal antibodies and to generate monoclonals against weakly immunogenic substances. In this first part of a two-part review, Matthew Scharff and his colleagues review the most useful of these modifications in the production of animal monoclonal antibodies, paying particular attention to the problem of raising antibodies against small amounts of weak immunogens.

UR - http://www.scopus.com/inward/record.url?scp=0022914711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022914711&partnerID=8YFLogxK

U2 - 10.1016/0167-5699(86)90142-8

DO - 10.1016/0167-5699(86)90142-8

M3 - Article

VL - 7

SP - 344

EP - 346

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 11

ER -